In the late 1970s the options for systemic antifungal therapy doubled with the addition of
intravenous miconazole and oral ketoconazole to the two previously available agents …

Human mycoses can be categorized as superficial, localized, or disseminated. Superficial
mycoses are generally confined to the skin and nails, whereas localized mycoses include …

Invasive fungal infections have extremely high rates of morbidity and mortality, particularly in
immunocompromised hosts. Combination antifungal therapy is conceptually attractive as a …

Invasive fungal infections will continue to cause major complications in
immunocompromized patients. At the moment, the expansion of antifungal drug research …

Major increases in the incidence of systemic fungal infections have been observed during
the past three decades, particularly in immunocompromised patients. A critical need exists …

Combination antifungal therapy has been an area of research and clinical interest since
systemic antifungals became available decades ago. In vitro and clinical data were …

Since the 1950s there has been an increase in the incidence of invasive fungal disease. The
first successful systemically administered antifungal drug, amphotericin B, was introduced in …

As invasive fungal infections in immunocompromised patients become increasingly
important, the field of antifungal chemotherapy continues to evolve rapidly. New agents have …

Invasive fungal infections are major causes of mortality in immunocompromised patients.
Despite improved outcomes with new antifungals, there remains a pressing need to further …

Invasive fungal infections remain a major cause of morbidity and mortality in
immunocompromised patients, and such infections are a substantial burden to healthcare …